{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:49:16Z","timestamp":1791305356467,"version":"4.3.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2020.100290","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T17:26:33Z","timestamp":1609003593000},"page":"100290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Analysis of bevacizumab treatments and metastatic sites of lung cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Hideomi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masachika","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Saikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2020.100290_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2020.100290_bib0002","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2020.100290_bib0003","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2020.100290_bib0004","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2020.100290_bib0005","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100290_bib0006","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2020.100290_bib0007","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctarc.2020.100290_bib0008","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2020.100290_bib0009","unstructured":"Cancer Treatment Center of America. https:\/\/www.cancercenter.com\/cancer-types\/lung-cancer\/stages\/stage-iv-lung-cancer (accessed 24 February 2020)."},{"issue":"Issue 1","key":"10.1016\/j.ctarc.2020.100290_bib0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100290_bib0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med"},{"key":"10.1016\/j.ctarc.2020.100290_bib0012","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Mundy Nat. Rev. Cancer"},{"issue":"Issue 1","key":"10.1016\/j.ctarc.2020.100290_bib0013","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-4975(96)00220-2","article-title":"Distribution of distant metastases from newly diagnosed non-small cell lung cancer","volume":"62","author":"Quint","year":"1996","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ctarc.2020.100290_bib0014","doi-asserted-by":"crossref","unstructured":"Oikawa A., Takahashi H., Ishikawa H., et\u00a0al. Application of conditional probability analysis to distant metastases from lung cancer Published online on: December 2011;23:629\u2013634, https:\/\/doi.org\/10.3892\/ol.2011.535.","DOI":"10.3892\/ol.2011.535"},{"key":"10.1016\/j.ctarc.2020.100290_bib0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1986.4.5.702","article-title":"Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study","volume":"4","author":"Finkelstein","year":"1986","journal-title":"J Clin. Oncol"},{"key":"10.1016\/j.ctarc.2020.100290_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data","volume":"23","author":"Hoang","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2020.100290_bib0017","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JTO.0b013e318260e106","article-title":"Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab","volume":"7","author":"Hoang","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100290_bib0018","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.21873\/anticanres.12779","article-title":"Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer","volume":"38","author":"Shiroyama","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctarc.2020.100290_bib0019","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","article-title":"The role of the Microenvironment in Liver Metastasis","volume":"22","author":"Tovah","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.ctarc.2020.100290_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ctarc.2020.100290_bib0021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.ctarc.2020.100290_bib0022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100290_bib0023","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma","volume":"181","author":"Kusmartsev","year":"2008","journal-title":"J. Immunol"},{"issue":"20","key":"10.1016\/j.ctarc.2020.100290_bib0024","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:33Z","timestamp":1762842153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220301258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":24,"alternative-id":["S2468294220301258"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100290","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of bevacizumab treatments and metastatic sites of lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100290"}}